Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

Publication ,  Journal Article
Blum, KA; Jung, S-H; Johnson, JL; Lin, TS; Hsi, ED; Lucas, DM; Byrd, JC; Cheson, BD; Bartlett, NL; Cancer and Leukemia Group B,
Published in: Ann Oncol
November 2010

BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma. PATIENTS AND METHODS: In part 1 of the trial, 16 patients received SGN-30 with GVD to assess the safety of the combination. In part 2, patients were randomly allocated to SGN-30 (n = 7) or placebo (n = 7) with GVD to determine overall response rate (ORR). RESULTS: ORR in all 30 patients was 63% (65% with SGN-30 plus GVD, n = 23, and 57% with placebo plus GVD, n = 7). Median event-free survival was 9.0 months, with no difference between the two arms. Grades 3-5 pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closure of the trial. All five patients with pulmonary toxicity had a V/F polymorphism in the FcγRIIIa gene (P = 0.008). CONCLUSIONS: Together with historical data demonstrating a 2% incidence of pulmonary events with GVD, these results indicate that SGN-30 cannot safely be administered concurrently. The risk of pneumonitis with SGN-30 and GVD is greatest in patients with an FcγRIIIa V/F polymorphism.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

November 2010

Volume

21

Issue

11

Start / End Page

2246 / 2254

Location

England

Related Subject Headings

  • Young Adult
  • Vinorelbine
  • Vinblastine
  • Treatment Outcome
  • Survival Rate
  • Receptors, IgG
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Neoplasm Staging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Blum, K. A., Jung, S.-H., Johnson, J. L., Lin, T. S., Hsi, E. D., Lucas, D. M., … Cancer and Leukemia Group B, . (2010). Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol, 21(11), 2246–2254. https://doi.org/10.1093/annonc/mdq211
Blum, K. A., S. -. H. Jung, J. L. Johnson, T. S. Lin, E. D. Hsi, D. M. Lucas, J. C. Byrd, B. D. Cheson, N. L. Bartlett, and N. L. Cancer and Leukemia Group B. “Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.Ann Oncol 21, no. 11 (November 2010): 2246–54. https://doi.org/10.1093/annonc/mdq211.
Blum KA, Jung S-H, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL, Cancer and Leukemia Group B. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol. 2010 Nov;21(11):2246–2254.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

November 2010

Volume

21

Issue

11

Start / End Page

2246 / 2254

Location

England

Related Subject Headings

  • Young Adult
  • Vinorelbine
  • Vinblastine
  • Treatment Outcome
  • Survival Rate
  • Receptors, IgG
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Neoplasm Staging